Back to Trials
NCT06605118PHASE3RecruitingAccepts Healthy Volunteers

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

The George Washington University Biostatistics Center

Start Date

11/6/2024

Completion Date

11/30/2027

Summary

This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection.

Detailed Description

This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either azithromycin prophylaxis or to placebo. All participants will receive standard of care preoperative antibiotics. The primary objective is to evaluate in patients undergoing scheduled/prelabor cesarean if pre-incision adjunctive azithromycin prophylaxis reduces the risk of post-cesarean infections compared with placebo. Secondary objectives include 1) to assess the perinatal and maternal safety of pre-incision adjunctive azithromycin, 2) to evaluate whether adjunctive azithromycin prophylaxis reduces maternal and neonatal resource use outcomes compared with placebo, and 3) to evaluate whether adjunctive azithromycin influences maternal and neonatal infection with resistant organisms compared with placebo. Individuals will be randomized prior to the start of the cesarean to either 500mg of intravenous azithromycin or to placebo (normal saline). Maternal blood and cord blood will be collected on a subset of the population. Research staff will abstract maternal and neonatal outcomes following delivery and discharge from the hospital. A single maternal follow-up study visit at 6 weeks (4-8 weeks) postpartum will be scheduled to ascertain maternal and neonatal outcomes.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: * ≥ 23 weeks' gestation (ACOG dating criteria) * Scheduled or prelabor cesarean delivery * Singleton or twin gestation Exclusion Criteria: * Allergy or contraindication to azithromycin or macrolide antibiotics, including those with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin * Chorioamnionitis * Bacterial infection (e.g., pyelonephritis) requiring ongoing antibiotic treatment after delivery * Premature rupture of membranes (PROM) or labor (i.e., contractions with ongoing cervical change) * Fetal demise or known major congenital anomaly * Azithromycin treatment within 7 days * Planned use of antimicrobial prophylaxis after delivery for any reason * Known structural heart disease or active cardiomyopathy (current ejection fraction\<40%) * Known arrhythmia with QT prolongation or taking scheduled medications known to prolong the QT interval such that it would preclude the use of azithromycin * Refusal or unable to obtain consent (e.g., language barrier) * Participating in another intervention study that influences the primary outcome in this study * Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, do not have to be excluded.

Interventions

DRUG

Azithromycin Injection

DRUG

Placebo

DRUG

Standard of Care Preoperative antibiotics

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Obstetrical ComplicationsLabor and Delivery ComplicationCesarean Delivery

Locations

University of Alabama - Birmingham

Birmingham, Alabama 35233

United States

Regents of the University of California San Francisco

San Francisco, California 94143

United States

Northwestern University

Chicago, Illinois 60611

United States

Columbia University

New York, New York 10032

United States

University of North Carolina - Chapel Hill

Chapel Hill, North Carolina 27599

United States

Duke University

Durham, North Carolina 27710

United States

Case Western Reserve University

Cleveland, Ohio 44109

United States

Ohio State University

Columbus, Ohio 43210

United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania 19104

United States

Magee Women's Hospital

Pittsburgh, Pennsylvania 15213

United States

Brown Univeristy

Providence, Rhode Island 02905

United States

Baylor College of Medicine

Houston, Texas 77030

United States

University of Texas - Houston

Houston, Texas 77030

United States

University of Utah

Salt Lake City, Utah 84132

United States